Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Camrelizumab + anlotinib + albumin-bound paclitaxel first-line phase II study in advanced triple-negative breast cancer
ChiCTR2200060859Phase 2Not yet recruiting
- Sponsor
- Affiliated Cancer Hospital of Xinjiang Medical University
- Start
- Jun 2022
- Modality
- Immune Checkpoint Inhibitors → Monoclonal Antibodies → Antibody-Based Therapeutics, Small Molecules
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of camrelizumab, anlotinib and paclitaxel in triple-negative breast cancer (TNBC), sponsored by Affiliated Cancer Hospital of Xinjiang Medical University. Primary endpoint: Progression-free survival. Planned start Jun 2022; status: not yet recruiting.
02
Drugs
camrelizumabanlotinibpaclitaxel
03
Conditions
triple-negative breast cancer (TNBC)
Beyond the preview
Go deeper on ChiCTR2200060859.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ChiCTR2200060859.